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Abstract 
Development of immune therapy requires an in-depth knowledge of immune cells, how they 
act in a tumour, and how they can be manipulated. Colorectal cancer (CRC) patients have 
shown less favourable outcomes with immune therapy compared to those with other cancers, 
but the reason for this is unknown. Myeloid cells are heterogeneous and plastic; this makes 
their associations with tumour progression, regression, or treatment failure difficult to 
determine. High dimensional analysis is an exploratory approach that can help visualise and 
characterise datasets from complex populations. Flow cytometry was used to obtain single cell 
data from CRC patient tumour, normal bowel, and blood samples. After trialing a conventional 
biaxial gating analysis strategy, I developed a novel high dimensional analysis strategy specific 
for the myeloid cell infiltrate in CRC. To develop this analysis pathway, I used multiple tools 
and determined flowSOM and tSNE are the most useful in my specific cancer immunology 
research. Using this analysis strategy I determined that the myeloid cell content of CRC patient 
blood is not representative of the myeloid cell infiltrate of the tumour. Inclusion of more 
parameters and further quantification of analysed data may in the future produce significant 
findings that are of clinical relevance. 
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1 Introduction 
1.1 Introduction to colorectal cancer 
Cancer is the second leading cause of morbidity and mortality worldwide (1). Colorectal cancer 
(CRC) is one of the most prevalent cancers worldwide and contributes to a high proportion of 
overall cancer mortality. In 2018, over 1 million new cases of CRC and over 500,000 deaths 
in CRC patients were reported (2). The highest rates of CRC are seen in developed countries, 
including Australia and New Zealand (1).  
 
Immune therapies are developed to modulate immune functions and can aid the body to directly 
kill cancer cells or help bypass cancer host evasion mechanisms (3). The colon is an especially 
immune rich, and tolerogenic environment so it could be expected that immunotherapies would 
be of benefit. However, many immune therapies are less successful in the treatment of CRC, 
compared to other cancers (4). Further investigation and characterisation of immune responses 
in CRC are needed to understand why immune therapies may fail, and to further the 
development of therapeutically effective immune therapies for CRC patients. 
 
1.2 The immune response to cancer 
Immune cells can initiate an inflammatory response to clear the body of mutated, dying, or 
dysfunctional cells (5). Immune cell involvement in the killing of cancer cells was first 
demonstrated in the 1970s (6). A 1973 study showed T cell and macrophage cooperation in the 
killing of virally induced cancer cells although the mechanism of killing at that point in time 
was unknown. The knowledge that the immune system can destroy mutated, pre-cancerous, 
and induced-tumour cells contributes to the rationale behind harnessing the immune system as 
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a cancer therapeutic. T cells have been well studied in immune therapy research as they initiate 
a cytotoxic response to specific antigens. (7). 
 
1.3 Roles of myeloid cells in cancer are unclear 
Myeloid cells make up a large proportion of tumour infiltrating immune cells (8, 9). Myeloid 
cells have broad functional roles as part of the immune system. Myeloid cells rely on 
recognition of pathogen or damage associated molecular patterns, or help from other 
cells/cellular products to initiate a response (10). The study of multiple myeloid cell subsets 
has shown inconclusive evidence regarding their roles in cancer (11, 12). 
 
1.3.1 Ontogeny of myeloid cells 
Myeloid cells can arise from haematopoietic stem cells in the bone marrow (13), or from an 
embryonic lineage. Myeloid cell development is complex but has been simplified here. A 
common myeloid progenitor develops into erythrocytes, megakaryocytes, mast cells, and 
myeloblasts. Myeloblasts further develop into monocytes, eosinophils, neutrophils, or 
basophils depending on environmental stimuli (14) (Figure 1). Monocytes mature into 
macrophages or myeloid derived dendritic cells (DCs) as they move from blood into tissues. 
 
1.3.1.1 Gut associated macrophages 
Since this thesis is focused on CRC it is important to note that there are myeloid cells that 
develop specifically from an embryonic lineage. There is evidence that a proportion of tissue 
macrophages in the gut are derived from this embryonic lineage (15). There is also evidence 
that macrophages exhibit tissue specific phenotypes (16), this is important to consider when 
studying specific tissues. Gut macrophages express the surface marker CD33 and lack common 
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macrophage markers CD14 and HLA-DR. (markers are proteins that are used to define cell 
subsets).  
 
These gut macrophages are especially tolerogenic, as the gut environment has a large bacterial 
load. A large proportion of these bacteria are commensal and benefit the host. Both the 
microbiota and immune system in the gut environment must be controlled to prevent infection 
in the gut while also maintaining balance to prevent excessive inflammation that could damage 
the gut barrier.  
 
Figure 1. Development of myeloid cells from a common myeloid progenitor cell. A common myeloid 
progenitor cell arises from a haematopoietic stem cell in the bone marrow (not pictured). Common 
myeloid progenitor cells develop into myeloblasts, erythrocytes, and megakaryocytes. Megakaryocytes 
give rise to platelets. Myeloblasts develop into monocytes, neutrophils, mast cells, eosinophils, and 
basophils in the blood. Monocytes further develop into myeloid derived dendritic cells and 
macrophages in the tissue (13). 
 
1.3.2 Myeloid cell subsets 
This thesis focuses on multiple pan-myeloid cell markers however, myeloid cells are massively 
heterogeneous and plastic. The definitions of cell subsets in this introduction and repeated 
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throughout this thesis are over-simplifications based on simple marker expression. These are 
definitions that researchers are beginning to move away from as the true diversity of these cells 




Macrophages are phagocytic cells. Macrophages are often characterised by the expression of 
CD14 (17). CD14 is a membrane glycoprotein that is involved in activation of macrophages 
(18). Macrophages can play a role in tumour progression through promotion of angiogenesis 
and extracellular matrix (ECM) remodeling (19). Macrophages can also play an anti-
tumorigenic role through direct or indirect killing of cancer cells (20), for example, through 
production of cytotoxic molecules such as reactive oxygen species (ROS) or the recruitment of 
cytotoxic lymphocytes.  
 
Macrophages have shown varying associations with cancer outcome. Macrophages are often 
defined as tumour associated macrophages (TAMs), or M1 and M2 macrophage subsets based 
on what cell surface proteins they express. However, these definitions do not explain the full 
complexity of macrophage subsets and will not be used here. Lack of a proper way to define 
macrophage subtypes impedes on the progression of macrophage research (21). Interestingly a 
high infiltration of CD163+ macrophages was associated with improved prognosis in CRC 
patients (22) in contrast to many other cancers which show a poor prognostic association with 
CD163+ macrophages (23, 24).  
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1.3.2.2 Dendritic cells 
Macrophages and DCs both arise from monocytes. These two cell types have an intricate and 
plastic relationship. CD11c is a marker used to separate macrophage and DC populations (25). 
DCs contribute to immunity through presentation of antigens to other immune cells and 
production of chemical messengers called cytokines (26). 
 
It is important to reiterate that the above definitions of these myeloid cell subsets are an 
oversimplification. It is likely that separating these populations and assigning them into groups 
based on a small cohort of chosen markers does not accurately represent their differences.  
 
1.4 Flow cytometry allows for single cell definition 
Fluorescently activated cell sorting (FACS or flow cytometry) is a tool for single cell analysis. 
Cell suspensions are incubated with fluorescently labelled antibodies specific to markers of 
interest. The use of the light spectrum to detect fluorophores allows for multiple parameters to 
be measured on individual cells in a single sample. Flow panel design involves developing a 
panel of markers conjugated to specific fluorophores that excite different lasers in the flow 
cytometer. Two fluorophores that are detected by the same laser cannot be differentiated. This 
is an essential consideration in panel design so that all cell surface proteins in the panel can be 
detected on a single cell.  
 
1.4.1 Markers for studying myeloid cell populations 
Sufficient markers must be used to study myeloid cells in CRC to separate populations. The 
markers CD3 and CD20 are restricted to T cells and B cells respectively so can be used to 
exclude these cells from analysis with a myeloid cell focus. CD11b is a marker my present on 
all myeloid cells and can be used to isolate myeloid cells for analysis. There is a large range of 
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markers that are pan-myeloid however, CD11b has been shown to be upregulated on 
macrophages in CRC tumours so is of interest in CRC research (27). 
 
CD14 is a marker often used to categorise macrophages in research however, some 
macrophages do not express CD14. Differential expression of specific markers within in a 
defined subset is one of the challenges that arise when studying myeloid cell subsets. CD11c 
positivity and CD14 negativity is a way to separate DCs from macrophages (28). CD33, as 
mentioned in section 1.3.1.1, is a marker that defines gut macrophage populations along with 
a lack of expression of the common macrophage marker CD14 (CD33+, CD14-). CD206 is the 
macrophage mannose receptor (29) and is often used to define macrophages subsets as anti-
inflammatory (30). CD127 is the interleukin-7 receptor and can be used as a marker to define 
pro-inflammatory cells (31). 
 
1.4.2 Problems that arise with markers and complex populations 
It is important to note that when developing panels of markers to research myeloid cell subsets 
the markers are chosen based on previous knowledge. This inherently introduces bias into 
studying these complex populations by trying to group them based on previously determined 
definitions. Many subsets defined in previous research do not consider the potential of marker 
co-expression and the level of marker expression on a cell. For example, myeloid derived 
suppressor cells (MDSCs) are a subset of myeloid cells that can infiltrate tumours and suppress 
immune functions MDSCs are a heterogeneous subset of myeloid cells, categorized as CD11b+ 
CD14+ HLA-DR- CD15- (32). Because of this definition, it can be hard to exclude MDSCs 
when studying other myeloid cell populations depending on how many parameters can be 
measured and what markers are available for detection. 
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Some research may include MDSCs in their macrophage populations depending on what 
markers the research has used. This shows how some cells can skew research findings if 
populations are not well defined. Definition is important in the study of heterogeneous cells 
such as myeloid cells. Moving away from simple population definitions and the use of high 
dimensional analytic tools is a way that may benefit the study of complex populations. 
 
1.5 Implications of myeloid cell plasticity and heterogeneity 
Plasticity is defined as the ability of a cell or organism to change to adapt to their environment. 
Plasticity makes grouping of cells challenging as a cell from one defined subset can evolve into 
a different subset in response to environmental stimuli. Because of this plasticity, it is likely 
that polarization states and cellular phenotypes exist on a spectrum with varying intermediates 
(33). 
 
Heterogeneity is defined as the quality or state of being diverse in character or content. Levels 
of protein expression and the co-expression of proteins contributes to cellular heterogeneity. 
The current knowledge around myeloid cell polarization, and the extent of plasticity and 
heterogeneity of these populations, specifically macrophages, remains incomplete and 
inconsistent (34). 
 
1.6 High dimensional analysis in immunology 
Plasticity and heterogeneity make population definitions complex. Using machine-based 
learning can aid in the understanding of heterogeneous cell populations. High dimensional 
analyses are exploratory approaches that allow analysis of multiple parameters at once within 
a dataset.  
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Conventional (manual) gating strategies use biaxial plots, but when working with complex 
datasets there is a quadratic increase of complexity with each new dimension (35). Manual 
gating also introduces bias as the user defines positive and negative populations. High 
dimensional analysis tools help researchers obtain an insight into the relationships between 
multiple proteins or other cellular features and eliminates bias introduced with manual gating. 
This type of approach is needed to understand complex populations and their functions.  
 
A detailed understanding of infiltrating cell populations into CRC may help uncover new 
markers or populations that could have potential implications in the growth, metastasis, or 
outcome of a patient’s cancer. There are data from high dimensional analyses specific for 
myeloid cell signatures in mice (36) but high dimensional myeloid analysis in humans is 
lacking in current research. 
 
High dimensional analytic tools can be accessed using computer software or web-based 
applications such as R, Cytobank, and OMIQ. These tools are algorithm based and are used for 
deep profiling. Deep profiling allows multiple parameters to be analysed simultaneously. 
Variations in levels of marker expression are harder to quantify in conventional analyses, high 
dimensional analysis is a way to circumvent this limitation of manual gating. There are multiple 
high dimensional analytic tools that can be used to analyse data, some are more similar than 
others however, the algorithms that they run all differ. High dimensional analytic tools have 
advantages and disadvantages that make them more or less suitable for specific data or specific 
research questions. 
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1.6.1 Dimensionality reduction visualises complex populations  
Dimensionality reduction is a tool that transforms multidimensional data into a two-
dimensional (2D) space that best represents the relationships and features of the data. The t-
Distributed stochastic neighbor embedding (tSNE) algorithm connects all features in a 
multidimensional space and then reduces the dimensions while retaining the features of the 
data in the output 2D visualisation (37). Dimensionality reduction algorithms require input 
variables from the user including 1) perplexity; the perplexity value chosen determines the 
balance between preservation of local and global structure (lower perplexity puts more 
emphasis on local population relationships); 2) number of iterations; iterations are runs of the 
algorithm and a large enough value is required to iterate the data to a stable configuration. 
However, a larger iteration value will cause the algorithm to run for longer and this can be an 
issue for large datasets.  
 
The t-SNE algorithm specifically runs non-linear dimensionality reduction. This is useful for 
biological data as it captures non-linear relationships (such as exponential and logistic data). 
The tSNE algorithm reduces dimensions while maintaining the distances between data points 
to preserve global and local data structure in an unsupervised manor (38). Use of the tSNE 
algorithm limits manual gating bias and has identified immune cell subsets that may be missed 
by manual gating. tSNE has been used to study the diversity of regulatory T cell subsets (39), 
and a variation of tSNE was used to study the lymphocyte compartment in CRC specifically 
(40). 
 
1.6.2 Clustering groups phenotypically similar cells 
tSNE and dimensionality reduction visualisations have the ability to retain the complicated 
spectrum of cell phenotypes that occurs within data. Clustering algorithms group cells into 
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populations and this loses some complexity of single cell phenotypes in the data. Losing a 
proportion of complexity in data can be an issue; however, the reason for using clustering is to 
group similar cells into populations and correlate these specific groups with disease or 
treatment outcomes. Clustering algorithms can define or identify novel cell populations with 
specific phenotypes. 
 
Clustering analyses can be supervised or unsupervised. Supervised clustering allows users to 
separate samples into groups before clustering; unsupervised clustering groups samples based 
on similarities after clustering. Unsupervised clustering analyses include Spanning-tree 
Progression Analysis of Density-normalised Events (SPADE) and flowSOM, a self-organising 
map. Clustering algorithms organise cells into a hierarchy of related phenotypes (41). 
Clustering facilitates analysis of heterogeneous populations and groups cells based on similar 
expression of multiple markers.  
 
Cluster analysis revealed that a subset of activated regulatory T cells was upregulated in CRC 
patient tumour compared with non-tumour bowel (NTB). It was hypothesised that this subset 
could play a role in anti-tumour responses (42). Clustering of myeloid cells in human CRC 
patients does not usually involve the use of these high dimensional tools (43). When high 
dimensional analysis has been undertaken in CRC only a narrow range of myeloid cell markers 
were used and further analysis is warranted (40). 
 
1.7 Gaps in current knowledge of myeloid cells in CRC 
Myeloid signatures have rarely been studied in CRC so this gap in current knowledge may bear 
some relevance to why immune therapies lack success in CRC. Knowledge of the tumour 
microenvironment (TME) in CRC as a whole is incomplete. My objectives with this research 
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aim to fill the gap and provide a larger picture of the myeloid cell compartment in CRC. This 
may in future have implications on our understanding of the involvement of myeloid cells in 
tumour progression, patient survival and treatment responses. Subpopulations of myeloid cells 
that are revealed to be significant to cancer outcomes will drive immunotherapy research, 
however, the initial steps in studying myeloid cells in cancer require improvement. 
 
1.8 Project Objectives 
My project objectives (post COVID-19 lockdown) are as follows 
1- Determine the best way to collect single cell myeloid data 
      1a- Design and optimise a flow panel to analyse myeloid cells in CRC patient 
tumour, NTB, and blood samples 
2- Develop and analyse data using a conventional gating strategy 
3- Compare multiple high dimensional tools to determine which are best suited for 
studying myeloid cells in CRC  
4- Compare conventional and high dimensional approaches  
5- Develop a novel a high dimensional analysis strategy to investigate myeloid cell 
populations in CRC and use it to analyse single cell data 
 
1.8.1 Project Considerations 
Conventional models of cancer use subcutaneous injection of cancer cells into mice. The Kemp 
lab has developed a surgical model of CRC, where tumours are injected into the caecum (44). 
This model may be a more accurate representation of the human immune cell infiltrate 
compared with models that use subcutaneous injection of cancer cells.  
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I intended to use flow cytometry and high dimensional analyses to determine if this murine 
model accurately represented the immune cell infiltrate in human CRC. However, due to 
COVID-19 lockdown after learning proper mouse handling techniques (Appendix 6.1) and 
processing for immune cell analysis, the Kemp lab decided to halt any further mouse work so 
my project changed and this objective was unable to be completed. Animal models with similar 
tumour responses and immune cell infiltrates will help us more accurately study the cancer and 
the effect immunotherapies may have on it. 
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2 Materials & Methods 
2.1 Reagents and buffers 
2.1.1 Phosphate buffered saline (PBS) 
160g sodium chloride (Scharlau, Barcelona, Spain), 4g potassium chloride (Sigma Aldrich, 
Missouri, USA), 4g monopotassium phosphate (Sigma Aldrich), and 22.7g disodium 
phosphate (Sigma Aldrich) was dissolved in 2L distilled water (dH2O) to make 10x PBS. PBS 
was diluted to 1x with dH2O for use. 1x PBS was filter sterilised under aseptic conditions and 
stored at 4ºC.  
2.1.2 Fluorescence-activated cell sorting (FACS) buffer 
Heat inactivated foetal calf serum (FCS; 5mL; PAA laboratories, Morningside QLD, Australia) 
and 0.1g sodium azide (PROLAB, Geldenaaksebaan, Germany) was added to 1L of 1x PBS to 
make 1x FACS buffer. 1x FACS buffer was filter sterilised under aseptic conditions and stored 
at 4ºC.  
2.1.3 Mammalian culture medium 
Complete Roswell Park Memorial Institute (RPMI) 1640 medium (ThermoFisher, Grand 
Island, USA) was supplemented with 5mL 100U/mL penicillin/streptomycin (Gibco, Life 
Technologies, Carlsbad, CA, USA), 500 L beta-2mercaptoethanol (Gibco) and 50mL heat 
inactivated FCS under sterile conditions and stored at 4ºC. 
2.2 Patient samples 
2.2.1 Ethical approval 
Use of patient tissues was approved by the Health and Disability Ethics Committee 
(14/NTA/033). Use of peripheral blood mononuclear cells (PBMCs) from healthy donors 
(HDs) was approved by the Ethics (Health) Committee of the University of Otago (H18-088).   
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2.2.2 Patient consent and recruitment 
Patients undergoing elective surgery for CRC at Dunedin Hospital were invited to participate. 
All patients gave written informed consent before participation in the study. 
2.2.3 Tissues and blood collection  
Sections of resected tissue were obtained and dissected by Dunedin Hospital staff. NTB 
samples were obtained from macroscopically normal appearing sections of the colon, 10cm 
away from the tumour. Tumour tissue samples were isolated from the primary tumour. Blood 
was collected on the same day prior to surgery. Fresh samples were transported on ice directly 
from Dunedin Hospital to the laboratory for immediate processing. Patient number, tissue 
weights, and cell number were recorded for all samples and this associated data was transferred 
to a CRC patient database. 
2.3 Tissue and blood preparation 
2.3.1 Blood preparation 
Whole blood was transferred to a 50mL Falcon tube (In Vitro Technologies, Auckland, NZ) 
and diluted 1:1 with 1x PBS. 15mL of Ficoll-paque PLUS (GE Healthcare, Chicago, Illinois, 
USA) was pipetted down the central hole of a SepMate-50 tube (STEMCELL Technologies, 
Vancouver, Canada). Diluted blood was then pipetted down the side of the SepMate-50 tube 
containing Ficoll-paque PLUS. The tube was spun with the brake on at 1200g for 10 minutes 
at room temperature. Heavier and more granular cells remained in the Ficoll, while enriched 
PBMCs in the supernatant were tipped off into a new 50mL falcon tube and washed twice in 
1x PBS. 
2.3.2 Tissue preparation (dissociation) 
NTB and tumour samples were transferred to separate wells of a 6-well plate (ThermoFisher 
Scientific, Australia). Tissues were covered in 5mL sterile StemProTM AccutaseTM Cell 
Dissociation Reagent (ThermoFisher Scientific). A scalpel was used to dissect the tissue into 
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smaller pieces to increase surface area. The 6-well plate was then incubated for 10 minutes at 
37°C 5% CO2. After incubation the samples were further dissected to maximise cell recall. The 
contents of the wells were then strained through MACS SmartStrainers (70um; Miltenyi 
Biotec, Bergisch Gladbach, Germany) into separate 50mL Falcon tubes (In Vitro 
Technologies). The wells were washed with RPMI to isolate any remaining cells and filtered 
into the corresponding Falcon tubes. Cells were then pelleted at 582 x g for 4 minutes at 4°C 
and the supernatant was discarded. Cells were washed with RPMI and resuspended in 1mL 1x 
PBS for counting.  
2.3.3 Cell counting  
10 L of the cell suspensions were transferred to a 96-well plate and diluted 1:1 in 0.1% Trypan 
Blue (Gibco, Life Technologies). Blood cell suspensions were counted with the Luna-2TM cell 
counter (Logos Biosystems, South Korea) and live cell concentration was recorded. Tissue cell 
suspensions (both tumour and NTB) were counted manually using a haemocytometer (Boeckel 
& Co. GmbH, Hamburg, Germany) under a light microscope. Cells that excluded Trypan Blue 
from there membranes were counted as viable. Cell numbers from haemocytometer counting 
were calculated using the following equation. 
Cells/mL = average cell number per quadrant x dilution factor (2) x 1x104. 
2.3.4 Storage of frozen cells 
Immune cells isolated from patients or HDs that were not used immediately were pelleted and 
resuspended in 1mL of freezing media. Freezing media consisted to 10 L of dimethyl 
sulfoxide (DMSO; Sigma Aldrich) and 900 L FCS. Cells in freezing media were transferred 
to cryotubes (Greiner Bio-One, Monroe, USA) and immediately transferred to a CoolCell 
cooling container (Biocision, San Rafael, California, USA) that was placed at -80°C for 
between 24 and 48 hours. Cryotubes were then moved from -80°C to liquid nitrogen for long 
term storage. 
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2.3.5 Defrosting 
Frozen samples from HDs or patients were defrosted from liquid nitrogen stores before 
processing. 10mL of RPMI per sample was warmed in a 37°C water bath before removing the 
cells from liquid nitrogen. Cryopreserved cells were thawed by pipetting the prewarmed RPMI 
onto the frozen sample. The thawed cells were transferred into 10mL of RPMI and immediately 
spun at 582 x g for 4 minutes at 4°C. The supernatant was then discarded. The pellet was 
washed again and resuspended in PBS for viability staining described in methods section 2.4.1. 
2.4 Flow cytometry 
A cytometry panel (Table 2) for the identification of myeloid cell subsets using antibodies 
conjugated to fluorophores with minimal spectral overlap and optimal resolution was designed.  
2.4.1 Viability staining 
Cells were washed in FACS buffer and resuspended in 1mL of 1x PBS. Cells were stained with 
either Live/Dead Zombie Green (BioLegend, San Diego, USA) or Live/Dead Zombie NIR dye 
(BioLegend) for 30 minutes on ice in the dark at a 1:1000 dilution to exclude dead cells from 
analysis. After incubation cells were washed with 500 L FACS buffer and resuspended in 
100 L of FACS buffer for extracellular staining. 
2.4.2 Extracellular staining  
A fraction of each cell suspension was set aside for unstained, and FMO controls (see methods 
2.4.3). Patient and HD samples were stained with the complete flow cytometry panel (Table 2) 
in 100 L FACS buffer. Samples were incubated for 30 minutes on ice in the dark. Cells were 
then washed with 500 L FACS at 582 x g for 4 minutes at 4ºC. The supernatant that included 
unbound antibodies was tipped off. 
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2.4.2.1 Fixing 
Cells were fixed with 1% paraformaldehyde (PFA; Sigma Aldrich). All samples, FMOs, and 
beads were incubated with 200 L of 1% PFA for 30 minutes on ice in the dark. Fixed samples 
were then washed with 500 L FACS buffer, the supernatant was tipped off and samples were 
resuspended in 200 L FACS buffer and stored in the 4°C fridge. Resuspended samples are 
then ready for acquisition using the BD LSRFortessa (see methods 2.4.7). 
2.4.3 FMOs and controls 
Unstained tissue and unstained blood samples were taken prior to viability staining. Live/Dead 
single-stained samples were also created as a control. One Live/Dead sample comprising cells 
killed with chilled 100% ethanol and another Live/Dead control comprising live cells were 
made. Fluorescence minus one (FMO) controls were made by staining samples with the whole 
antibody panel minus one antibody of interest. An FMO for every marker on the panel, except 
Live/Dead was made. For example, the CD45 FMO was stained with all markers except CD45. 
FMOs were stained as described in the previous section and washed/fixed simultaneously with 
the complete stained samples. 
2.4.4 Single-stained beads for compensation 
Samples comprising of 1 drop of OneComp eBeads (eBiosciences, San Diego, CA, USA) were 
stained with 1 L of their respective antibody to make single-stained controls. A single-stain 
was made for every marker on the panel excluding Live/Dead as a single-stained Live/Dead 
control was made using cells (see methods 2.4.3). The single-stain controls were incubated in 
the dark on ice for 30 minutes and fixed with PFA alongside the samples and FMOs. 
2.4.5 Antibody titrations 
All antibodies were titrated using PBMCs from HDs to determine the most appropriate dilution 
for staining. PBMCs were isolated from whole blood and resuspended in 400 L FACS buffer. 
This cell suspension was then split between four FACS tubes and each sample was incubated 
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with one of various antibody concentrations (1:20, 1:40, 1:80, 1:160) in the dark on ice for 30 
minutes. Samples were washed after incubation. Titrated samples were run on the BD 
LSRFortessa and analysed using FlowJo (version10.7.1, Tree Star, OR, USA). The optimal 
titration value was chosen by selecting the one with maximum resolution, minimum 
background staining, and appropriate separation of positive and negative populations.  
2.4.6 Compensation 
Voltages and compensation values were determined using the FACSDIVA software (BD 
Biosciences) using single-stained comp eBeads (eBiosciences; methods 2.4.4). The Live/Dead 
compensation control used was made by killing cells from either HD PBMCs or patient 
samples and stained with viability dye as described in methods section 2.4.3. 
2.4.7 Acquisition 
Data acquisition was performed on the BD LSRFortessa using the FACSDIVA programme 
(version 8.0, BD) A minimum of 100,000 events and a maximum of 500,000 events were 
recorded from each sample. Data was exported as flow cytometry standard 3.1 (FCS3.1) files. 
These FCS3.1 files were then transferred to FlowJo (Version 10.7.1) for conventional analysis, 
or Cytobank for high dimensional analysis. 
2.5 Analysis 
Compensation and conventional analysis were done using FlowJo software (Version 10.7.1). 
FMOs were used as a guide for placing positive and negative cell gates. Any analysed data that 
was not obtained by myself was obtained by Jessica Harte of the Kemp Laboratory with the 
same staining and acquisition procedures. 
2.5.1 High dimensional analysis 
The Cytobank web application was used to conduct high dimensional analyses. Tools including 
SPADE, viSNE, and flowSOM were used to analyse FCS3.1 files on the Cytobank server. The 
OMIQ web application was used for a brief period to run UMAP and flowSOM analyses. 
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Analyses, and the methods trialed to use these tools make up a large proportion of the results 
obtained and are covered in more depth in both the introduction and results. 
2.6 Contribution by other Researchers 
Fran Munro (Department of Surgical Sciences, University of Otago) recruited and collected all 
CRC patient tumour, NTB, and blood specimens. Analysis was performed by myself, with 
some advice from Joanna Roberts (Flowjoanna) and Dr Felix Marsh-Wakefield (University of 
Sydney). Ginny Niemi euthanized all mice used and assisted with processing mouse lymph 
nodes, spleens, and tumours. 
2.7 Research and funding 
Funding for this research is from the Cancer Research Trust (human) and University of Otago 
Research Grant (mouse). Research was undertaken in the Kemp lab in the Department of 
Microbiology and Immunology. 
2.8 Mouse experiments 
Some animal work was done (Appendix 6.1) but due to COVID-19 lockdown after learning 
proper mouse handling and dissection techniques all mouse work was halted and the research 
project was changed. Staining of immune cells isolated from mouse tissue was described as for 
human cells in methods section 2.4. 
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3 Results 
3.1 Project aims and overview 
Overall aim: To develop a novel high dimensional analysis strategy to investigate myeloid cell 
populations in CRC and use it to analyse single cell data 
1- Determine the best way to collect single cell myeloid data 
1a - Design and optimise a flow panel to analyse myeloid cells in CRC 
2- Develop and analyse data using a conventional gating strategy  
3- Compare multiple high dimensional tools to determine which are best suited for 
studying myeloid cells in CRC 
4- Compare Conventional and high dimensional approaches 
5- Develop a novel a high dimensional analysis strategy to investigate myeloid cell 
populations in CRC and use it to analyse single cell data 
 
I designed a workflow diagram based on how I intended to address the aims stated above 
(Figure 2). Both conventional and high dimensional analysis strategies were developed to 
determine the best way to study myeloid cells in CRC. I developed a novel analysis pathway 
to achieve accurate representations of the myeloid cell infiltrate from CRC patient blood, NTB, 
and tumours. 
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Figure 2. Workflow diagram proposed to study the myeloid cell infiltrate of colorectal cancer. Blue 
boxes represent steps prior to data analysis. Orange boxes represent a conventional gating analysis 
to quantify differences between patient and healthy donor bloods, and between patient tumour and 
normal bowel samples. Green boxes represent the high dimensional analysis pathway developed 
during this research and the algorithms included. 
 
3.2 Data acquisition using flow cytometry 
To determine the best way to study myeloid cells in CRC, and answer the first aim, single cell 
data must be acquired. Flow cytometry uses light scatter and the properties of fluorescently 
tagged antibodies to characterise single cells in a fluid sample. To use flow cytometry, a panel 
of fluorescent antibodies must be designed and optimised. 
 
Flow panel design requires knowledge of markers of interest, fluorophores and their brightness, 
and laser excitation. Initial panel design is shown in Table 1. Table 2 shows the optimised panel 
after changes were made. Live/Dead stains are excluded from living cells so the stain is only 
detected in dead cells and allows for these to be excluded from analysis. CD45 is a marker 
Design a flow panel using fluorescent 
antibodies
Collect single cell data
Develop novel analysis pathways
Conventional manual analysis pathway 
(FlowJo)
Analyse differences in marker expression 
between patient and healthy bloods
Analyse differences in maker expression 
between patient tumour and NTB infiltrates
High dimensional analysis pathway (Cytobank
online server)
Run dimensionality reduction (tSNE)
Clustering of single cell data 
(FlowSOM)
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present on all haematopoietic cells, this includes immune cells and immune cell precursors. 
CD3 and CD20 are both included in panel design to exclude lymphocytes from analysis. 
CD11b is a marker specific for myeloid cells. Research has shown that CD11b can be 
upregulated on macrophages in the tumour (27). CD11c is present on DCs and macrophages. 
DCs do not express CD14 so we can use CD14 positivity to separate these populations. 
However, some macrophages can lose expression of CD14. The heterogeneity of these 
populations makes separation difficult. During panel design using CD14 and CD11c was the 
best option available to separate macrophages and DCs. 
 
CD127 and CD206 are markers that separate pro-inflammatory and anti-inflammatory 
populations respectively. CD56 was included as this marker can be used to measure activation 
on DCs. CD33 is a marker expressed by CD14- gut homing macrophages. Since this research 
is focusing on CRC CD33 is included in an attempt to determine whether tumour infiltrating 
macrophages were recruited from patient blood or expanded from previously existing gut 
resident populations. 
 
Table 1. Initial flow panel design (all antibodies from BioLegend). 
Specificity Cell Fluorophore 
conjugate 
Clone Dilution 
CD45 Pan immune cell BV605 HI30 1:40 (2.5 L) 
Live/dead  - Zombie Green - 1:100 (1 L) 
CD3 T cell AF700 UCHT1 1:160 (0.625 L) 
CD20 B cell PerCP/Cy5.5 2H7 1:20 (5 L) 
CD11b Pan-myeloid PEcy7 ICRF44 1:160 (0.625 L) 
CD11c  DCs/monocyte APC 3.9 1:80 (1.25 L) 
CD14 Macrophage PE/Dazzle HCD14 1:160 (0.625 L) 
CD206 Activation APC/Cy7 15-2 1:40 (2.5 L) 
CD127 Antigen experience PE A019D5 1:80 (1.25 L) 
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CD56 Adhesion BV510 HCD56 1:40 (2.5 L) 
CD33 Gut homing BV421 WM53 1:160 (0.625 L) 
 
Table 2. Final and optimised flow panel (all antibodies from BioLegend). 
Specificity Cell Fluorophore 
conjugate 
Clone Concentration 
CD45 Pan immune cell BV605 HI30 1:40 (2.5 L) 
Live/dead  - Zombie L/D NIR - 1:200 (0.5 L) 
CD3 T cell AF700 UCHT1 1:160 (0.625 L) 
CD20 B cell PerCP/Cy5.5 2H7 1:20 (5 L) 
CD11b Pan-myeloid PEcy7 ICRF44 1:160 (0.625 L) 
CD11c  DCs/monocyte APC 3.9 1:160 (0.625 L) 
CD14 Macrophage PE/Dazzle HCD14 1:160 (0.625 L) 
CD206 Activation BV711 15-2 1:160 (0.625 L) 
CD127 Antigen experience BV786 A019D5 1:80 (1.25 L) 
CD56 Adhesion BV510 HCD56 1:40 (2.5 L) 
CD33 Gut homing BV421 WM53 1:160 (0.625 L) 
 
3.2.1 Changes made for flow panel optimisation 
Changes to original panel design were made as part of the optimisation process (compare 
Tables 1 and 2). Firstly, CD206 was moved from the APC/Cy7 channel to BV711. This was to 
get better resolution of CD206 detection as originally conjugated to APC/Cy7, a dimmer 
fluorophore than BV711. CD206 is not highly expressed on cells so a brighter fluorophore 
increases detection of CD206 expression; this was important because I wanted to investigate 
whether the TME comprised more anti-inflammatory or pro-inflammatory cells, which is 
known to differ among patients (45). 
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As CD206 was moved to a channel on the violet laser the Live/Dead dye was moved from 
Zombie Green to Zombie L/D NIR. Zombie L/D NIR could not be used originally because the 
fluorophore is detected by the same laser as the APC/Cy7. 
 
CD127 originally conjugated to PE was also moved to the violet laser and conjugated to 
BV786. PE is a dim fluorophore and CD127 is expressed at low levels, similar to CD206. I 
made this substitution because I wanted to investigate whether the TME comprised more anti-
inflammatory or pro-inflammatory myeloid cell subsets as stated above. 
 
CD206 and CD127 were substituted with conjugates to fluorophores in the violet channel to 
increase their detection. However, with these changes, now 5 out of 11 of the antibodies in the 
optimised panel were detected by the violet laser. Brilliant Violet Stain Buffer (BSB) was 
added to all samples stained using the optimised panel. This was a precautionary measure 
included as multiple fluorophores in the violet channel can spill over and interfere with 
detection. BSB prevents interactions between violet dyes that may cause staining artefacts that 
could affect interpretation of the data. 
 
When looking at high dimensional analysis data, mutually exclusive markers including CD3 
and CD11b were expressed on the same cells (data shown in appendix 6.5). Myeloid cells 
express Fc receptors (FcRs) that in a biological context bind the Fc portion of antibodies 
targeted to microorganisms to promote phagocytosis of the invading organisms. Because of 
FcR expression myeloid cells can bind the Fc portion of some antibodies that are used for 
staining. The addition of an Fc receptor blocking solution (FcX) was included to prevent this. 
FcX binds to FcRs present in the sample before incubation with antibodies used for staining. 
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This prevents non-specific binding of FcRs to the Fc portion of antibodies that are used to stain 
cells. 
 
3.2.2 Antibody titration determines optimal staining concentrations 
Another consideration when optimising a flow panel is the concentration of each antibody 
needed to stain samples for accurate data. To determine optimal staining concentration 
antibodies are titrated before use. PBMCs from HDs were isolated and used at 1x106 cells/mL 
for each titration. Antibody concentrations of 0.625 L, 1.25 L, 2.5 L and 5 L per 100 L of 
cells were titrated. The values were chosen as they test around the recommended concentration 
from the manufacturer. These concentrations are 1:160, 1:80, 1:40, 1:20 dilutions and the 
volumes above correspond to the dilution in 100 L of staining buffer. The concentration that 
showed the best separation between the negative and the positive populations was used. 
Titration of CD206 BV711 showed that 0.625 L (1:160 dilution) was sufficient to separate the 
positive and negative cell populations (Figure 3). More titration examples can be seen in 
appendix 6.3. Final titration values for every antibody are shown in Tables 1 and 2. 
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Figure 3. CD206 BV711 titration value 0.625 L is sufficient to separate positive and negative 
populations. FlowJo plots showing 1x106 PBMCs stained with varying dilutions of CD206 BV711. 
Left to right, top to bottom, 5 L, 2.5 L, 1.25 L, 0.625 L. 0.625 L (1:160 dilution) was sufficient to 
separate CD206 positive and negative populations. FSC-W, forward scatter-width. PBMCs, 
peripheral blood mononuclear cells. Analysis undertaken in FlowJo v10. 
 
3.3 Overview of analysis pathways 
To complete the second and third aims; develop and analyse data using a conventional gating 
strategy and; compare multiple high dimensional tools to determine which are best suited to 
analyse myeloid cells in CRC I developed two analysis pathways. The first pathway developed 
was a conventional analysis strategy (Results 3.4) and secondly, a high dimensional analysis 
pathway (Results 3.8). 
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3.4 Analysis of the myeloid cell infiltrate using conventional gating 
The second aim was to develop a conventional analysis pathway to analyse the myeloid cell 
infiltrate in CRC patients. Using the optimised flow panel (Table 2), data was analysed using 
conventional biaxial gating in FlowJo v10. FlowJo is downloadable software that takes FCS 
files and allows for manual changes in compensation and manual gating of populations in 
acquired data. FlowJo also has built in statistical tests that can be used. 
 
Firstly, how do we find populations of interest in our data? The population of interest in this 
research was live single CD45+ cells that were CD3- CD20- and CD11b+. Gating this way 
allows identification of myeloid cells and removal of any other cell types that could skew 
analysis. To isolate myeloid cells, I developed a gating strategy for use in FlowJo to identify 
live single CD45+ CD3- CD20- CD11b+ cells (Figure 4). 
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Figure 4. A biaxial gating strategy that allows isolation of CD11b+ myeloid cells. From left to right, 
top to bottom, this gating strategy used a time gate to remove any areas of uneven event acquisition, it 
then isolates single cells, lives cells, and subsequently CD45+ CD3- CD20- CD11b+ myeloid cells. 
FMOs were used as a reference to guide gating to isolate positive and negative populations for the 
respective markers. Gating was undertaken in FlowJo v10, plots are coloured by density. FMO, 
fluorescence minus one. 
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Unstained blood, unstained tissue, and FMOs were used to guide gating and discriminate 
positive and negative populations for isolation of CD11b+ myeloid cells (Figure 4). This gating 
allowed removal of unwanted cells from the data. CD3+ and CD20+ cells were excluded from 
analysis so no lymphocyte cells remained in the data that could influence results. 
 
A time gate and single cell gate were also included to remove any stream disruption and doublet 
cells from our analysis. A wide singlet gate was used because myeloid cells can be large and 
internally complex. Samples were also checked for antibody aggregation and this was removed 
(see Appendix 6.4). From this point antibodies were spun prior to staining to prevent 
aggregation. 
 
Once CD11b+ myeloid cell data was isolated in FlowJo, other markers of interest in the panel 
were investigated (Figure 5). CD14- CD33+ gut macrophage populations were isolated for 
quantification. CD14- CD11c+ DCs were identified, and activation of DCs using CD56 
positivity was investigated. CD206 and CD127 were analysed together to investigate the 
expression of these anti-inflammatory and pro-inflammatory markers on CD14+ macrophages.  
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Figure 5. Biaxial gating defines myeloid cell subpopulations. Biaxial gating was used to define 
CD14+ and CD14- populations. From there CD33+ CD14- gut macrophages were isolated. CD14- 
CD11c+ DCs were also isolated, and from this population. CD56+ activated DCs were identified. 
Expression of CD206 and CD127 was quantified on CD14+ macrophages. FMOs guided placement of 
gates to isolate populations of interest. Gating was undertaken in FlowJo v10, plots are coloured by 
density. Numbers indicate the proportion of the population that lies inside the gate. DC, dendritic 
cell. FMO, fluorescence minus one. 
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After development this manual gating strategy was applied to multiple samples (HD blood, 
CRC patient blood, tumour, and NTB) from multiple experiments and the proportions of 
specific populations were quantified and compared between sample types (Results 3.5). 
 
3.5 Conventional analysis of single cell data 
3.5.1 The proportion of immune cells in patient blood differs from HD blood 
To look at differences in immune cell infiltrates of HD and CRC patient blood first I quantified 
the proportion of overall immune cells in the blood of both of groups. The TME of many cancer 
types is characterised by a high infiltrate of myeloid cells (46). CD45+ cells include those of 
myeloid and lymphocyte lineages. I also quantified the proportion of immune cells that were 
CD11b+ myeloid cells in HD and CRC blood. 
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Figure 6. Proportions of myeloid cells and gut macrophages do not differ between CRC patient and 
HD blood. A. the proportion of CD45+ cells is significantly lower (p=0.0027) in the blood of CRC 
patients than HDs. Triangles indicate frozen samples and circles indicate fresh samples. B. Percentage 
of total CD33+ CD14- gut macrophages in the CD11b+ myeloid cell population does not show any 
significant differences between CRC and HD blood. C. The proportion of CD11b+ myeloid cells does 
not differ between HD and CRC patient blood. CRC, Colorectal cancer. HD, healthy donor. Non-
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The proportion of total CD45+ immune cells in the blood was significantly lower in CRC 
patients than in HDs (Figure 6A). Triangles indicate frozen samples. Frozen samples had 
higher frequencies of CD45+ cells than fresh samples, which was interesting, but was not 
investigated further due to time restrictions. 
 
3.5.2 There were no significant differences in myeloid cell subsets between patient and HD 
blood 
CD14- CD33+ gut homing macrophages were present at low levels in both CRC and HD blood 
with no significant differences (Figure 6B). There were no significant differences in the 
frequency of CD11b+ myeloid cells out of the total CD45+ immune cell population between 
CRC patients and HDs (Figure 6C). 
 
3.5.3 There were no significant differences in CD11b+ myeloid cells and gut macrophages 
between the tumour and NTB. 
I investigated differences in the proportions of myeloid cell subsets in the NTB and tumour 
tissues of CRC patients. This analysis was done to determine whether a larger proportion of 
infiltrating macrophages in the CRC tumour were recruited from the blood or expanded from 
gut macrophages already present at the site. Quantification of CD33+ CD14- gut macrophages 
showed no significant differences between the NTB and tumour (Figure 7A). Proportion of 
CD14+ macrophages did not differ between the tumour and NTB (Figure 7B). The results here 
show no significant differences between both gut macrophages and CD14+ macrophages 
between the CRC tumour and NTB samples. 
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Figure 7. There are no significant differences in gut macrophages, CD14+ macrophages, or expression 
of CD206 and CD127 between tumour and NTB CRC patient samples. A. percentage of total CD11b+ 
myeloid cells that are CD33+ CD14- gut macrophages dis not differ between NTB and the tumour. B. 
Percentage of total CD11b+ myeloid cells that are CD14+ macrophages did not differ between NTB 
and tumour. C. Levels of CD206 and CD127 expression on total CD11b+ myeloid cells did not differ 
between NTB and tumour. N = 7 CRC patients. Non-parametric t test was undertaken. CRC, colorectal 
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There were no significant differences between the expression of both CD206 and CD127 (anti-
inflammatory and pro-inflammatory respectively) markers on CD11b+ myeloid cells between 
the tumour and the NTB. 
 
DCs could not be quantified as there was too much variation between patients, especially with 
low cells numbers in the NTB samples. Low cell numbers skewed the results and showed large 
variation in the proportion of DCs and DC activation between patient tumour and NTB samples 
(data not shown). 
 
3.6 Cell number limitations impact visualisation of rare populations 
Myeloid populations are complex and some cells such as CD56+ DCs are only present at low 
numbers in the tumour. Since one of the aims was to determine the best way to study myeloid 
cells in CRC, I wanted to answer the question: does cell number impact the results we are able 
to obtain, and thus the resolution of our findings, especially for rare populations? 
Quantification of CD56+ DCs and CD33+ CD14- gut macrophage populations are low when 
the event acquisition number is set to 100,000, as these subsets are rare in blood (47). 
Acquisition was increased from 100,000 events to 400,000 events per sample to investigate the 
affect increasing the acquisition number has on rare populations (Figure 8).  
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Figure 8. Cell number impacts findings of rare populations in blood. A. Positive expression of CD56 
can be separated into high and low levels of expression when event number is raised. B. Positive 
expression of CD33 can be separated into high and low levels of expression when event number is 
raised. One patient did not show high and low levels of CD33 expression. FMOs were used to guide 
differentiation of positive and negative populations. n = 3 CRC patient samples. Analysis was done in 
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An increase in event capture provides better definition of populations that are rare (Figure 8). 
Higher cell recall allowed us to manually separate CD56+ DCs and CD33+ CD14- gut 
macrophage populations into populations with high and low levels of expression. Being able 
to stratify low and high expression of markers is useful but event acquisition must be high 
enough to separate populations with manual gating.  
 
From this point on I increased acquisition to around 300,000 events per sample; however, this 
was not always possible as some samples did not have enough cells. A large proportion of cells 
in the NTB and tumour samples were not immune cells so even though acquisition was high 
only a small proportion of events captured were immune cells. 
 
3.7 Summary of results from conventional analysis  
The results in this section show no significant differences between HD and CRC patient blood, 
or between patient NTB and tumours. It quickly became obvious that manual gating was not a 
sufficient tool to analyse populations that are extremely complex.  
 
3.8 High dimensional analysis 
High dimensional analysis provides a way that both co-expression of multiple markers and the 
levels of their expression can be included in analysis, manual gating is not sufficient to analyse 
these types of relationships. An understanding of different high dimensional tools will help 
achieve the fifth aim; Develop a novel high dimensional analysis strategy to investigate 
myeloid cell populations in CRC and use it to analyse single cell data.  
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3.8.1 Comparison of high dimensional analysis tools 
Before development of a novel high dimensional analysis strategy, I had to determine which 
tools were of the most benefit for myeloid cell research in CRC. The third aim of this research 
is to compare multiple high dimensional tools to determine which were best suited for studying 
myeloid cells in CRC. 
 
Multiple tools including SPADE, flowSOM, UMAP, and tSNE were trialed. Cytobank and 
OMIQ, two online servers were used to run and compare these high dimensional analytic tools. 
tSNE and UMAP, two dimensionality reduction algorithms were compared (Results 3.8.1.1), 
and SPADE and flowSOM, two clustering algorithms were compared (Results 3.8.1.2). 
 
The final developed analysis was Cytobank based and comprised tSNE dimensionality 
reduction, followed by clustering using flowSOM, and the visualisation of metaclusters on the 
single cell tSNE data. This will be covered more thoroughly in later sections (Results section 
3.9). 
 
In this section all analyses were undertaken on matched patient samples consisting of tumour, 
NTB, and blood. These files have been gated manually to clean raw data, and to isolate single 
live CD45+ immune cells or CD45+ CD3- CD20- CD11b+ myeloid cells. 
 
3.8.1.1 tSNE is more suitable for dimensionality reduction of myeloid cell data than UMAP 
To achieve the third objective, I wanted to answer the question; what is the best way to visualise 
single cell data in an informative way? I chose to trial two dimensionality reduction algorithms 
to achieve this. 
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Dimensionality reduction is a tool for visualisation and exploration of data. Dimensionality 
reduction tools run multiple iterations of the data until the dimensions within the data are 
reduced into a 2D space, while retaining as much information from the data as possible. Both 
tSNE and UMAP, which are dimensionality reduction algorithms, were used here. 
Dimensionality reduction was done on tumour, NTB, and blood samples from single patients 
in a single run. After the algorithm was run the cells from each specific file (blood, tumour, 
NTB) were separated onto their respective plots, allowing for comparison of single cell data 
between samples. 
 
UMAP has a faster run time and better preservation of global data structure than tSNE (37). 
Distances between groups are meaningful and represent similarity in UMAP. However, 
myeloid cells are massively heterogeneous and have large amounts of cross over within 
themselves. The UMAP plots that were run did not fully separate cell populations. Lack of 
separation was probably due to the complex spectrum of myeloid cell phenotypes (Figure 9).  
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Figure 9. UMAP dimensionality reduction did not separate single cells in a myeloid dataset. A. 
Blood. B. NTB. C. Tumour. UMAP plots were created from a single CRC patient’s blood, tumour, 
and NTB samples. UMAP plots are coloured by density with red areas indicating high density of cells 
and dark blue areas indicating low density of cells. Analysis was undertaken in OMIQ. CRC, 
colorectal cancer. NTB, non-tumour bowel. UMAP Uniform manifold approximation and projection 
for dimension reduction. 
. 
The tSNE algorithm was run and the output visualised on viSNE pots. (Figure 10). To run 
tSNE multiple parameters require user definition, these parameters include; perplexity, 
iterations, a seed, and a theta value. Multiple outputs were run as trialing different parameter 
values is recommended as it can change the visualisation of the data. Changes in the parameter 
settings will make small changes in how the data is reduced and will provide multiple slightly 
A B
C
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different outputs. This is important to do to make sure any features of the data that are seen and 
interpreted are not just an artefact of a single run.  
 
Incorrectly run algorithms can show features such as relationships in the data that are not 
actually there. The relationship or feature must be seen over multiple runs of the algorithm for 
it to be deemed a real feature of the data. If it is not seen in multiple runs then the relationship 
may only be a feature of a run with those specific parameters (37). However, the use of custom 
parameters can also bias the tSNE output and therefore, the global structure that is seen may 
be artefactual. This too, is why multiple runs with different values are important for the 
exploration of features of a dataset. 
 
  42 
 
Figure 10. tSNE coloured by CD11b, CD14, CD3, CD11c, CD206, and CD56 in the CRC tumour. 
From left to right, top to bottom, tSNE dimensionality reduction plots coloured by expression level of 
CD11b, CD14, CD3, CD11c, CD206, and CD56. Red areas of the plots correspond to high levels of 
expression of the coloured marker, dark blue areas correspond with no expression of the marker. 
CD3 is expressed at low levels because conservative manual gating was done to eliminate most cells 
expressing high levels of CD3. CD14 and CD11c are expressed only in areas of the data that express 
CD11b (validation that staining has worked). CD206 is only expressed at low levels in the dataset. 
CD56 is only expressed on an extremely small number of cells in the data. Iterations: 1,000. Seed: 42, 
Perplexity: 50. 100,000 events equally sampled. Theta: 0.5. Analysis was undertaken in Cytobank. (v), 
channel included for dimension reduction. tSNE, t-distributed Stochastic Neighbor Embedding. 
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The tSNE plot shown in Figure 10 only shows the tumour sample of a patient to demonstrate 
the tSNE output. tSNE accurately separated the cells and expression of myeloid markers could 
be visualised. Multiple runs were analysed and expression of mutually exclusive markers was 
not seen to validate the data. 
 
The lack of visualisation of separate groups on UMAP made it less useful for the myeloid cell 
data that was input. The tSNE plot provided separation of single cells and groups within the 
data and allowed visualisation of which cells in the data were expressing markers of interest. 
This result determined that tSNE was better suited for myeloid cell data and the aims of this 
research. 
 
3.8.1.2 FlowSOM provides more informative visualisations of clustering data than SPADE 
To answer the aim of what tools are the best to study myeloid cells in CRC I also chose to 
investigate two clustering algorithms. Clustering identifies populations based on multiple 
recorded parameters and groups similar cells together. Clustering data can be used to 
investigate population dynamics and associations rather than relationships between single cells 
in the data. 
 
When running clustering a user defined number of clusters within the data is created. A user 
defined number of metaclusters in the data are also created. Metaclusters are larger, broad 
clusters that group smaller clusters together based on their overarching similarity. 
 
SPADE and flowSOM, two clustering algorithms were compared to determine which was most 
appropriate for analysing myeloid cell data in CRC (Figure 11). Clustering algorithms were 
run using matched blood, tumour, and NTB samples. Clusters in the data were separated onto 
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respective plots for blood, tumour and NTB. The size of clusters (circles) corresponds to the 
density of cells in the cluster. Clusters are connected by nodes, the nodes are determined by 
the hierarchal relationships of clusters. The length of the node corresponds with the similarity 
of the clusters. FlowSOM and SPADE plots created from the same patient data and similar 
parameters were used to compare the two tools (Figure 11). 
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Figure 11. Clustering algorithms provide plots that visualise clusters and quantitative information 
about the clusters. A. SPADE clustering of a myeloid cell dataset from a CRC patient (blood, tumour, 
and NTB samples), the SPADE plot corresponding to the tumour is shown here, coloured by density. 
B. flowSOM clustering of the same myeloid cell dataset, tumour plot is also shown here. FlowSOM 
clusters are coloured corresponding to levels of marker expression as seen in the reference. Height of 
the coloured segment within the cluster corresponds to level of expression of the marker on that 
A
B
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cluster. In both plots nodes connect related clusters, length of node corresponds with the similarity of 
the two joint clusters. FlowSOM was run with a cluster number of 100, SPADE was run with a cluster 
number of 200, both plots were run with an iteration value of 1,000. Both plots display a dense region 
where the algorithm has struggled separate similar clusters spatially. Analysis was undertaken in 
Cytobank. CRC, colorectal cancer. NTB, non-tumour bowel. SPADE, Spanning-tree Progression 
Analysis of Density-normalised Events. 
 
Both SPADE and flowSOM plots returned plots that had cluster aggregation around a single 
point in the data. To visualise expression of markers on SPADE clusters the user must manually 
go through and look at multiple SPADE plots coloured corresponding to different markers. The 
SPADE plot above (Figure 11A) is coloured by density (number of cells in the cluster). Red 
corresponds with a dense cluster (large number of cells within the cluster) and dark blue 
corresponds with a less dense cluster (less cells within the cluster). Size of the clusters also 
correspond with cell density on SPADE plots.  
 
FlowSOM plots visualise expression of all markers in each cluster on a single plot called a star 
plot (Figure 11B). Each cluster is represented as a circle. Each circle is separated into segments, 
with one coloured segment representing each marker, this can be seen in the key. The height 
of the segment within the cluster represents the mean intensity of expression. For markers that 
are highly expressed within a cluster the whole segment will be present. For example, focusing 
on the dark blue segment in each cluster it can be concluded that CD11b is present on all cells 
(as it should be, as a pan-myeloid marker) however, it is represented at higher levels on some 
clusters when comparing all clusters on the plot. 
 
3.8.1.2.1 Myeloid cell plasticity makes separation of populations using clustering difficult 
Next, I wanted to determine why there was a large aggregation of clusters in the data on both 
plots as this was something that I had not seen before. Phenotypically similar cells cluster 
together and lie closer together on the plots based on how related they are. Choosing a cluster 
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number that is too high can cause populations of cells that are phenotypically similar to be 
separate. The user defined cluster number was decreased from 100 to 36 in an effort to prevent 
this overlapping visualisation of phenotypically different, but related populations (Figure 12). 
 
 
Figure 12. Decrease in flowSOM cluster number did not reduce myeloid cell data aggregation. The 
flowSOM algorithm was run with a cluster number that had been decreased from 100, the 
recommended value, to 36. When the flowSOM cluster number is decreased overlapping clusters are 
reduced but the number of clusters that expand away from the aggregation at the centre is also 
reduced. Height of coloured segments within the flowSOM plot correlates with the mean level of 
expression of the corresponding marker in the key. Nodes connect related clusters and node length 
corresponds with similarity of the clusters. Analysis was undertaken in Cytobank. Iterations, 1,000. 
 
Decreasing the cluster number to as low as 36 (Figure 12) did not prevent the large populations 
from being represented over top of each other on the flowSOM visualisation. When cluster 
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number was decreased not only was the aggregation still present but a large proportion of the 
populations that were more phenotypically dissimilar from the populations that were 
aggregating was lost.  
 
I hypothesised that the heterogeneity and plasticity of myeloid cells was a potential reason for 
phenotypically different clusters to overlap in this way. To test this, lymphocyte and myeloid 
cell data from patient tumours were clustered using flowSOM and differences between the 
flowSOM output data was compared. Lymphocyte data from a CRC patient stained with a flow 
cytometry panel of similar size to the myeloid data that is being investigated here was used to 
compare between myeloid and lymphocyte clustering data (Figure 13).  
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Figure 13. FlowSOM plots comparing the myeloid cell infiltrate to the lymphocyte infiltrate in CRC 
patient tumours. Both plots have used the same parameters to run. 1,000 iterations, 100 clusters, 10 
metaclusters, seed value 42. A. myeloid cell flowSOM plot based on 9 myeloid clustering channels, 
run on a myeloid cell dataset from a CRC patient (tumour, NTB, and blood samples included). B. 
Lymphocyte flowSOM plot based on 8 lymphocyte clustering channels, run on a lymphocyte dataset 
from a CRC patient (tumour, NTB, and blood samples included). Lymphocyte data was obtained by 
A
B
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Jessica Harte from the Kemp laboratory. Size of each circle corresponds to density of cells in the 
cluster. Height of the coloured segment corresponds to the mean level of expression of that marker in 
the cluster (see key). Nodes connect related clusters, length of node corresponds with similarity. 
Analysis was undertaken in Cytobank. CRC, colorectal cancer. NTB non-tumour bowel. 
 
FlowSOM plots were created to compare the clustering of the myeloid cell and lymphocyte 
cell infiltrates in CRC patients. Lymphocytes separate into clusters that were more defined, 
and had less overall similarity than myeloid cells. Myeloid cell clusters aggregate on the plot, 
some aggregation is seen in the lymphocyte dataset but not the extent that it is seen in the 
myeloid cell data. 
 
Some potential reasons behind this overlap of similar clusters in myeloid cell data include the 
heterogeneity and plasticity of these cells. Myeloid cell phenotypes are not as well 
characterised as lymphocyte cell subsets currently are. The clustering algorithm may be trying 
to find points at which the spectrum of phenotypes in myeloid cell data can be broken up. This 
was seen in both SPADE and flowSOM plots so it is not likely that it is an algorithmic problem 
but rather an intrinsic feature of myeloid cell data. 
 
3.8.1.2.2 Metadata is not easily interpretable when embedded on a flowSOM plot 
The overall aim of this research was to determine the best way to analyse single cell myeloid 
data. A dimensionality reduction tool and a clustering tool that provided the most accurate 
representations of the data were determined. However, the fifth aim was to develop a novel 
high dimensional analysis strategy to investigate myeloid cell populations in CRC. I wanted 
my high dimensional analysis strategy to be a tool that researchers can use to identify 
differentially expressed populations that can then be investigated and characterised. To create 
an analysis pathway that is useful in research it must also be user friendly and easily 
interpretable. 
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The aggregation of clusters on the myeloid cell flowSOM plot makes it difficult to interpret 
differences in single clusters so I decided to visualise metacluster data instead. Metaclusters 
encompass multiple smaller clusters. Differences in metacluster abundance should be more 
obvious when visualised. However metacluster data was not easily interpretable using the 
flowSOM plots that were produced. Two visualisations that flowSOM produced to explore 
metacluster data from the experiment can be seen in Figure 14. 
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Figure 14. Visualisation of metacluster data from flowSOM. Metaclusters are groupings of the most 
phenotypically similar clusters in the myeloid cell dataset. A & B. Circles correspond with 100 clusters 
in a myeloid cell dataset from a CRC patient (blood, tumour, and NTB samples). Different metaclusters 
are represented by the highlighted colours surrounding the individual clusters. Metacluster 
comparisons are not easily made using flowSOM plots. Comparison of metacluster data between 
samples (tumour, NTB, blood) cannot be visualised with flowSOM. Analysis was undertaken in 
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Metaclusters were visualised on top of normal clustering data. Inside the cluster is a digit that 
correlates to cluster number (Figure 14). The colour highlighting the outside of the cluster is 
indicative of the metacluster to which it belongs. In this plot a large proportion of clusters, 
around half, belong to a single metacluster.  
 
Visualising metadata this way makes it difficult to identify differences between samples, such 
as when comparing NTB and tumour samples. Metadata is not provided in this way for each 
star plot, one can only visualise metaclusters on a single plot showing relative cluster size over 
all samples. A table of values for metacluster and cluster data are provided for each sample for 
reference or investigation after visualisation of the plots. 
 
To visualise differences in metacluster abundance flowSOM plots are not useful. The next 
challenge was to determine how to visualise differences in metacluster abundance between 
patient samples. I wanted to determine a way to do visualise differences in metacluster 
abundance so I could compare the myeloid cell content of CRC patient blood and tumours. 
This sub aim is to determine whether blood is an accurate representation of the myeloid cell 
infiltrate of the tumour. If differences at the metacluster level are seen then this is an indication 
that populations from our clustering data are most likely differentially expressed between 
samples, and therefore the blood is not an accurate representation of the tumour.  
 
3.9 Visualisation of metacluster data on tSNE provided two layers of 
information on a single plot 
Metacluster data overlaid onto single cell data represented on tSNE plots provided a way to 
combine and visualise two analyses at once. Results from the use of previous tools helped guide 
the design of this final step in my analysis pathway (Figure 14). To determine if CRC patient 
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blood is representative of the tumour infiltrate, I overlaid metacluster data onto previously 
made tSNE plots (Figure 15). 
 
 
Figure 15. Blood is not an accurate representation of the myeloid cell metaclusters that are present 
in the same patients tumour. A. blood B. Tumour. Blood and tumour tSNE plots from the same CRC 
patient show differential expression of metaclusters. tSNE plots are coloured by 10 metaclusters 
determined using flowSOM analysis. Multiple metaclusters, numbered 2, 3, 4, and 6 are 
overrepresented in the tumour compared with the blood. Metacluster 2 is overrepresented in the 
blood compared with the tumour. Spatial differences in the abundance of cells from metacluster 9 can 
also be seen. Colour key corresponds to both plots. Analysis was undertaken in Cytobank. Iterations, 
1,000. Seed 42, Theta 0.5, perplexity 50. Clusters 100, metaclusters, 10. CRC, colorectal cancer. 
tSNE, t-distributed Stochastic Neighbor Embedding. 
A
B
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3.9.1 Patient blood metacluster data was not representative of the tumour data 
Metacluster data shows disproportionate representation of the metaclusters between the blood 
and the tumour (Figure 15). Each dot is a single cell and the colour of the dot corresponds to 
the metacluster it is grouped into. In the blood, metacluster 3 (red), metacluster 2 (green), 
metacluster 4 (purple), and metacluster 6 (pink) were lowly represented; however, these 4 
metaclusters were highly represented in the tumour. Metacluster 8, in comparison, was present 
at lower levels in the tumour and at higher levels in the blood. 
 
The data above concludes that metacluster prevalence in the blood is not an accurate 
representation of the tumour. Some studies do use patient blood to understand the tumour (48), 
and while this approach does have benefits, like the detection of circulating tumour DNA 
(ctDNA) and circulating tumour cells, myeloid immune cell subsets infiltrating the tumour do 
not seem to be represented in equal proportions in the blood. However, it is important to 
mention that statistical analysis has not been covered as the high dimensional data analysis thus 
far has been limited to single patients. The difficulty that arises when trying to concatenate 
patient samples collected on different occasions is part of the reason for this. 
 
3.10 Density of cells on tSNE is not informative if sampling is not proportional  
I hypothesised that there would be minor differences between the tumour and NTB myeloid 
cell infiltrate. However, isolating immune cells from NTB can be limiting in regard to the 
proportion of the event count that are actually immune cells. This number was even lower when 
only myeloid cells are included in analysis. 
 
I compared tSNE plots of blood, tumour, and NTB from a single patient and coloured it by cell 
density. Three tSNE plots, representative of patient tumour, blood, and NTB respectively show 
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that density is not proportional among samples (Figure 17). Again, the data here indicate that 
event count can impact on interpretation of results, as was shown with conventional gating 
(Figure 8 and Appendix 6.6). 
 
 
Figure 16. Density of myeloid cells differs between tumour and blood of the same patient. Differences 
in density cannot be seen with NTB samples due to low cell number. tSNE plots show the CD11b+ 
myeloid cell infiltrate representing three CRC patient tissues. A. tumour B. blood C. NTB. Plots are 
coloured by density of cells, red represents high density and black represents low density. There is a 
difference in density of cells that can be seen on each plot. The lower right region of cells were 
present at higher densities within the blood compared with the tumour. It is difficult to compare 
density of cellular infiltrates when the same sized cell infiltrate has not been used between samples. 
The lack of CD11b+ events in the NTB sample made it unsuitable for comparison with the blood or 
tumour of the same patient. Analysis was undertaken in Cytobank. A & B 40,000 events, C 6,000 
events. Iterations, 1,000. Seed 42, Theta 0.5, perplexity 50. CRC, colorectal cancer. NTB, non-tumour 
bowel. tSNE, t-distributed Stochastic Neighbor Embedding. 
A B
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Figure 16 highlights the difficulty of comparing samples with uneven numbers. NTB samples 
have low counts of myeloid cells and this made it difficult to compare the NTB myeloid cell 
infiltrate with tumour and blood infiltrates. Blood and tumour had similar samples sizes, and 
the myeloid cell infiltrates of these two samples showed a clear difference in density on their 
respective tSNE plots. The dense upper region of cells in the tumour (Figure 16A) 
corresponded with a sparse region of cells in the same position one the tSNE blood visualisation 
(Figure 16B). Cells that were more prevalent in blood, such as the cells in the bottom right 
halves of the tSNE plots were present in the tumour but at lower densities. 
 
It was concluded that it is easy to visualise differences in density between the tumour and blood 
plots. However, it was not possible to compare tumour and NTB samples in this way due to 
lack of data points. This is validated with manual gating (Appendix 6.6) that shows how density 
or frequency of cells in samples can skew visualisations and thus interpretation of the data. 
This phenomenon is called frequency bias; frequency bias gives an illusion that makes results 
seem skewed purely due to the differences in the number of events being compared.  
 
3.10.1 Down-sampling events allows for accurate comparisons of cellular infiltrates 
The inability to compare density of cells due to uneven event numbers among samples led to 
the next question; if down-sampling is done on all plots, does this provide accurate 
representations, and allow for comparison of the representative infiltrates?  
 
This question was answered by looking at differences in metadata when tSNE plots for all 3 
samples types from a single patient were down-sampled. Down-sampling is when an equal 
proportion of events is displayed on every plot. The value that is sufficient for down-sampling 
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is often the value of the events in the smallest sample, in this case, NTB. Down-sampling allows 
comparison of cell infiltrates in an accurate way (Figure 18). Although the plots look more 
scarce compared to the other tSNE plots, this is purely the result of down-sampling and does 
not affect comparisons.  
 
 
Figure 17. Down-sampling on tSNE allows accurate comparison between the patient tumour, NTB, and 
blood. A. The blood, is not a representative of B. the tumour and C. the NTB. The NTB shows some 
differences when compared to the tumour. Metacluster key corresponds to all samples. Metaclusters 
allow another layer of information to be visualised over single cell data. Down-sampling allows for 
accurate comparison between samples. Metacluster 2 is present in both NTB and tumour tissues but 
extremely lowly represented in the blood. Analysis was undertaken in Cytobank. 6,000 data points 
(events) shown on each tSNE plot. Iterations, 1,000. Seed 42, Theta 0.5, perplexity 50. CRC, colorectal 
cancer. NTB non-tumour bowel. tSNE, t-distributed Stochastic Neighbor Embedding. 
A B
C
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Interestingly, metacluster 1 (blue) was largely expressed in all three plots however, the density 
of its expression on the tSNE plot differed between the blood and the two tissues. This also 
suggested perhaps the metacluster number could be increased as it might separate two 
potentially different but similar metapopulations. Metacluster 2 (Met 2; green) was low in the 
blood, but highly expressed in NTB and tumour. Met 2 seemed to be expressed at a higher 
level in the NTB than in tumour, but this claim cannot be made without quantification. 
Metacluster 5 (brown) was differentially expressed between samples. Metacluster 5 was 
present at low levels in the blood, moderate levels in the NTB and high levels in the tumour. 
(0.4% of the infiltrate in blood, 2.9% in NTB, 7.1% in tumour).  
 
This visualisation identified metaclusters to further investigate. I have investigated Met 2 here, 
but not multiple metaclusters as this was beyond the scope of this research. Met 2 abundance 
in each sample is as follows. Met 2 is present at 0.5% of the myeloid cell infiltrate in the blood, 
26.6% in NTB, and 15.3% in the tumour. I looked further into the data tables produced by the 
flowSOM algorithm and found that Met 2 had low expression of CD33, CD14, CD45, and 
CD56. It had very high expression of CD206, an anti-inflammatory marker and no expression 
of CD127, a pro-inflammatory marker. it had medium to high levels of CD11c expression. 
 
3.11 Conclusions from high dimensional analysis  
Myeloid cell data is massively complex, especially when myeloid cell clustering is compared 
to lymphocyte clustering. The data demonstrate how difficult it may be in the future to define 
specific myeloid cell populations based on a small cohort of markers. The heterogeneity and 
intermediate phenotypes of these cells, as shown by high dimensional analysis, are far beyond 
the current methods used, such as defining them with single markers. These tools have shown 
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how complex it is to study these cells - tools that allow us to understand high dimensional 
datasets are needed to find real correlation and response data.  
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4 Discussion 
The aim of this research was to determine the most optimal way to study myeloid cells in CRC. 
I developed a novel high dimensional analysis pathway to investigate the unique myeloid cell 
populations present in CRC patient blood, tumour, and NTB (Figure 18). I have determined 
that blood is not representative of the myeloid cell populations that are present in the tumour. 
I also demonstrated that the differences between myeloid cell populations in tumour and NTB 
can be visualised using my novel analysis strategy. Application of this pathway to large 
myeloid cell datasets with multiple dimensions of data in future will allow thorough 
investigation of myeloid cells infiltrating CRC patient tissues. 
 
I determined through the use of both conventional and high dimensional analyses that 
conventional biaxial gating is not sufficient for exploring complex populations, such as the 
myeloid infiltrate. Conventional gating is not sufficient as it only provides limited definition 
of cell subsets of interest and manual gating of these populations introduces bias. Development 
of an analysis workflow required a large amount of understanding about the collected data, the 
analytic tools of interest and their suitability to the dataset and research questions. High 
dimensional analyses allow data to be explored and removes the aspects of manual gating that 
can introduce bias that masks real or creates false associations. 
 
4.1 Metacluster visualisation can be used to compare samples in a dataset  
Metaclusters are large groups of clustered data. Metaclusters encompass numerous 
phenotypically similar clusters present in the dataset of interest. For example, multiple subsets 
of macrophages that are phenotypically different and cluster separately are likely to be 
represented in a single metacluster (49).  
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One of the aims of this research was to find a way to visually represent clustering data to allow 
comparison of the myeloid cell infiltrates between samples. Visualisation of metaclusters on 
tSNE plots provided a good way to represent the data. tSNE visualisations were useful when 
looking for cell subsets, specifically metaclusters, that vary in incidence between sample types. 
Including visualisation of metaclusters on tSNE plots in the analysis workflow developed here 
provides a means for easily interpretable results. The use of flowSOM for clustering provides 
a way to quantify these differences with output data once they have been visualised. 
 
This thesis has demonstrated that metaclusters are not easily interpretable when visualised on 
the initial flowSOM plots that are produced (Figure 14), and this prevented the comparison of 
metacluster abundance between samples. This was solved by overlaying metacluster 
abundance data on single cell data (tSNE plots). Dimensionality reduction was run prior to 
clustering to retain single cell definition. tSNE provided a visualisation of metacluster 
abundance and the output data from flowSOM can be used to quantify results. Using this 
analysis, researchers in future will be able to find differentially expressed populations in 
myeloid data that warrant further investigation. 
 
4.2 Myeloid cell heterogeneity impacts analysis 
Differences between myeloid cell and lymphocyte data was seen when the two datasets were 
clustered with the same parameter values and 8-9 lineage specific markers (Figure 13). 
Lymphocyte subsets were well separated when analysed with the clustering tool flowSOM. 
Myeloid cell subsets when analysed the same way produced clustering data that prevented 
visualisation of clearly distinguished populations. Multiple clusters of myeloid cells on the 
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flowSOM plot overlapped and looked to aggregate on top of one another at a single point on 
the map. 
 
Aggregation of clusters could be an example of over-clustering. Over-clustering occurs when 
the cluster number, a user defined parameter, is set too high. Clusters with no actual phenotypic 
differences are created when a dataset is over-clustered. The overlapping clusters were not 
removed when the cluster number was decreased with the aim of combining these similar 
clusters. Definition of clusters in the data that were further away from each other, suggesting 
they were more phenotypically different were lost instead (Figure 12). The issue with losing 
this definition is that under-clustering removes subtle or rare populations from the data (50). 
Some level of over-clustering is necessary to separate the subtle populations from larger groups 
of cells. Over-clustering provides high resolution that can improve the identification of rare 
cell subsets (51). 
 
The results above suggest that although similar, the myeloid cell clusters that aggregate on top 
of one another on the map are phenotypically different populations. This may suggest that there 
are not enough dimensions on the flowSOM plot to accurately represent the similarity between 
the clusters. It is likely that the clusters were all phenotypically related to one another in a way 
that cannot be accurately represented in 2D. They may aggregate because they are related in a 
way that requires more definition, such as a three-dimensional (3D) representation to express 
the relationships between the clusters in the data.  
 
Manual gating is often used to identify and characterise myeloid cell populations. Sufficient 
gating strategies to isolate myeloid populations of interest do exist (52) however, the literature 
on myeloid cell subsets is constantly evolving and new subsets within defined populations 
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continue to arise (53). Along with the results above this suggests that manual gating is not a 
sufficient approach to separate myeloid cell populations. The use of manual gating also requires 
prior knowledge of what populations will be present in a specific dataset and this biases what 
populations will be found. Myeloid cells are more heterogeneous and complex than manual 
gating is likely to be able to accurately define, as even some high dimensional tools are unable 
to visually represent the heterogeneity in the data in a comprehensible way. 
 
4.3 Tailoring analyses to the dataset of interest is necessary 
Comparison of two different datasets (myeloid and lymphocyte) analysed with the same 
clustering tool showed how different data can be expressed using the same algorithm and 
parameter settings. UMAP plots emphasise global data structure and the use of UMAP to 
analyse myeloid cell data produced a visualisation that showed little separation between cells 
(Figure 9). Lack of separation made it difficult to quantify groups of cells within the data, such 
as macrophages and DCs. Together, these results suggest that tailoring analysis to the dataset 
of interest is an essential part of obtaining accurate representations of data.  
 
When cells were gated manually to a CD45+ CD3- CD20- CD11b+ population a large 
proportion of the diversity in sample was lost. Other cell subsets contribute to the diversity of 
immune cells. For example, T cells, B cells, and myeloid cells are all largely phenotypically 
different. If a sample of PBMCs was analysed using flowSOM greater separation of clusters 
would be expected due to large differences between lymphocyte and myeloid cell populations. 
 
A potential contributing factor to the aggregation of clusters seen in both SPADE and 
flowSOM plots could be the myeloid cell dataset that the algorithm analysed (Figure 10). While 
myeloid cells are heterogeneous within themselves many subsets still express a proportion of 
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the same markers. Overlapping marker expression can make it difficult to separate populations, 
as is seen here. This is likely because a panel of only 8 markers was used and some of the 
markers included in the panel (Table 2) are expressed on a range of different myeloid cells. 
More definition, such as a larger panel would be needed to more accurately separate myeloid 
cell populations. 
 
Due to lack of measurable parameters MDSCs may be included in the CD14+ macrophage 
subset defined here (54). MDSCs could potentially have been excluded using CD33 CD14 
double positivity, however, there is literature that defines subset of MDSCs that are CD14- 
CD33+ CD11b+, which would be included in the gut macrophage subset defined in this research 
(55). This adds to the conflicting data surrounding myeloid cell subsets and to the knowledge 
that increasing detectable parameters will be the best way to define myeloid cell populations 
and separate them in future. 
 
4.4 The myeloid cell content of blood is not representative of the tumour 
myeloid cell infiltrate 
Part of the fourth aim was to determine if the myeloid cell content of patient blood was 
representative of the tumour and conventional gating was unable to answer this. Immune cells 
can migrate between tissue and the blood and research has shown the ability to detect tumour-
reactive and mutation specific immune cells (specifically lymphocytes) in the circulation of 
melanoma patients (56). Other research uses blood as a means to detect ctDNA (57). If blood 
was representative of the tumour this would provide an easy and less invasive way to study the 
myeloid immune cell infiltrate of CRC patients. In future this would allow therapies that target 
specific immune cell populations to have their probability of success in patients determined 
through investigation using blood. 
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The analysis strategy developed here demonstrated that the myeloid cell populations in the 
blood were not representative of the tumour (Figure 15). Multiple metaclusters that were 
present in the tumour were not present in the blood suggesting the colon or the tumour itself is 
a more diverse environment. Differences in cells density between blood and tumour samples 
(Figure 16) also provides evidence that the blood is not representative of the tumour. Some 
subsets of myeloid cells such as macrophages and DCs are known to migrate from the blood 
into tissues where they then mature, this could be a contributing factor to the differences seen 
(58).  
 
There is evidence that macrophages that infiltrate into tumours are influenced by the local TME 
(27). Signals in the TME can favour the development of macrophages with an anti-
inflammatory phenotype (59). Anti-inflammatory macrophages produce tumour growth factor 
β (TGF-β) that contributes to ECM remodelling and angiogenesis, promoting tumour growth 
and metastasis (60). Anti-inflammatory macrophages also contribute to immune suppression 
in the TME (59). 
 
Perhaps initial stages of disease would be more representative of blood however, it is unlikely 
that the myeloid cells present in blood will ever be accurately representative of the tumour or 
gut. Tissue specific cells such as gut macrophages and tissue resident macrophages are present 
in gut tissues and would skew representative populations. These cells will be present at the 
tumour site and will likely also be influenced by the TME. The NTB is probably a better sample 
to compare infiltrating populations. Comparing populations between tumour and NTB may 
uncover cell subsets enriched in the tumour that are promoted by signals from the TME. These 
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populations could be further investigated and correlated with patient disease outcomes or 
targeted for therapy. 
 
4.5 Down-sampling can cause information to be lost in visualisations 
This research compared blood and tumour samples at a high resolution by comparing a large 
number of myeloid cells from each sample. Down-sampling was used to compare tumour and 
NTB cell infiltrates. With down-sampling small metaclusters became extremely lowly 
represented on the tSNE plots (Figure 17). The limitation of this approach is that it is no longer 
possible to visualise differences in rare populations as cells are removed randomly during 
down-sampling. Although a large proportion of the cells removed during down-sampling will 
come from overrepresented metaclusters, cells from rare populations will also be lost. However 
if down-sampling is not done results can be confounded and frequency bias can make 
populations look overrepresented in some samples compared with others. 
 
Loss of the ability to compare rare populations may cause researchers to disregard small 
populations that are lost on the visualisations. The danger with this is that there is a chance 
these smaller metaclusters could be differentially expressed, i.e. not present in one sample and 
present in low numbers in another sample. Small cell subsets still have the potential for 
implications in disease. Use of flow cytometry and single cell RNA sequencing has 
characterised a rare population of DCs expressing high levels of OX40 that promote anti-
tumour immunity (47). Rare populations such as this would not be found if event acquisition 
was low or down-sampling was required. This result further expands the implications that 
frequency bias, and levels of marker expression can have on analysis. 
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4.6 High dimensional analyses uncover previously undefined populations 
Clustering allows investigation of populations that do not fit typical definitions of cells. This 
allows a move away from conventional definitions of cell populations. In this thesis metacluster 
2 (Met 2) was investigated. Met 2 was highly expressed in the NTB, moderately expressed in 
the tumour, and very lowly expressed in the blood. However, the significance of the differences 
in abundance of this population was not investigated as it is beyond the scope of the research. 
 
Met 2 was investigated using the output CSV files from the flowSOM analysis. Average 
expression levels of the flow panel markers on met 2 were analysed (Figure 17). Met 2 
expressed high levels of CD206, an anti-inflammatory marker that is highly expressed on 
TAMs. However, met 2 lacked expression of CD14, and CD33, meaning it did not fit into the 
standard definition of either a macrophage or a gut macrophage. Met 2 also expresses CD11c 
at moderate levels which is a marker used to isolate DC populations.  
 
There is potential that met 2 could fit into a definition of an MDSC but there are multiple 
MDSC definitions it does not fit. MDSCs are usually CD14+ and CD11b+, however there are 
subsets that are CD11b+ CD14- (32). There is also evidence some monocytic MDSCs express 
CD33 (55). Expansion of these monocytic MDSCs has been seen in cancers such as breast, 
glioblastoma, and melanoma. There is no proper standardisation of MDSC markers so it is very 
difficult to determine what this population may be (61). 
 
To find real populations multiple patient samples would need to be concatenated to find a 
feature of metacluster abundance across patients. This is because the 10 metaclusters from 
multiple other patients will differ slightly due to interpatient variation and batch effects.   
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4.6.1 Batch effects prevent experimental alignment 
Batch effects occur when non-biological factors in an experiment are the cause of differences 
in the data that is produced. Factors that can contribute to batch effects include temperature, 
variations in protocol and timing, and instrumental variations.  
 
Batch alignment is undertaken to line up experimental runs and combine them into one 
analysis. Batch alignment methods are computationally intensive, and batch alignment tools 
continue to be developed to allow increased scaling of experiments and collaborations. Batch 
balanced k-nearest neighbors (BBKNN) is code that has been developed and used on large-
scale mouse data to create a map of the cells from multiple (at least 26) mouse organs from 8 
datasets (62). 
 
During the course of this research one of the lasers on the BD LSRFortessa that the samples 
were run on was changed. It is known that instrumental variations and set up can introduce bias 
into analysis. Replacing a deteriorating laser requires a new, and therefore brighter laser to be 
introduced. This may cause the marker that was originally detected by that laser to suddenly 
seem over expressed in samples. This is purely due to the increased level of signal detection 
now a brighter laser has been put in place.  
 
Batch alignment requires a reference group. A reference group would for example, be blood 
from the same donor taken at one time point that is then frozen in aliquots and processed in 
every experiment. This way any variations in detection of markers on that sample can be 
concluded to have come from technical variations and not variations within the sample itself. 
This will help align samples from multiple batches if they all have the same reference group 
included. A reference group was not available at the time of conducting this research. 
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4.7 Conventional gating introduces bias 
Conventional analyses include user defined gates that denote specific populations on biaxial 
plots. Usually these gates define the positive and negative populations corresponding to 
specific markers. Bias is introduced when researchers use manual analysis to look for a specific 
population or feature of the data. With machine learning a large proportion of user defined 
features are removed so bias is limited. However, this can make high dimensional tools more 
difficult to use and the results difficult to interpret. 
 
Conventional gating is also limited in its accuracy. A tSNE plot gated down to CD11b and 
dimensionality reduction run on what should be a CD45+ CD3- CD20- CD11b+ population is 
shown in Figure 9. The prior manual gating was done conservatively in an effort to prevent 
removal of any myeloid cells from the dataset as myeloid cell recall can often be low. When 
the tSNE algorithm was run CD20 and CD3 were included in the channel values to make sure 
any residual lymphocytes clustered together and did not confound the conclusions made for 
myeloid cell data.  
 
Lymphocytes were excluded because some of the myeloid markers included in the panel (Table 
2) can be expressed on specific types of lymphocytes. Lymphocytes are not the focus of this 
research and any novel populations found should be CD11b+ CD3- and CD20-. However, when 
the tSNE plot was explored a large proportion of the cells in the data were lymphocytes that 
expressed low levels of CD3. Research has shown that subsets of lymphocytes have differing 
levels of CD3 expression (63). CD8+ cytotoxic T cells express lower levels of CD3 than some 
subsets of CD4+ T cells. This suggest that less conservative gating should be undertaken to 
remove theses populations from analysis of myeloid cells. 
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The presence of T cells expressing low levels of CD3 explains why the value on the expression 
axis for CD3 is between 0 and 8,000 (Figure 10). CD3 is highly expressed on some 
lymphocytes and if we compare this to CD11b, a marker that is highly expressed on myeloid 
cells the expression axis for CD11b ranges from 0 to 1x106. Lowly expressed markers such as 
CD56 have expression axes that range from around 0-9,000. The reason for low CD3 
expression is because cells expressing high levels of CD3 were excluded from analysis using 
manual gating. The reason for low expression of CD56 is because it is a marker expressed at 
low levels on cells. This result contributes to the conclusion that knowledge of the dataset of 
interest is important for analysis, and if populations are not excluded from analysis properly 
these can confound results. 
 
4.8 Limitations and strengths 
One of the limitations of the research conducted here include batch effects. Batch effects limit 
the analyses we can do. CITRUS is a supervised clustering tool that was initially going to be 
used. CITRUS requires at least 8 samples per group for analysis and it was not possible for this 
many samples to be processed at once. Lack of availability of fresh samples also contributed 
to lac of samples. The only way this tool could have been used was with a reference to align 
batches.  
 
Lack of definition, such as restriction to the use of only seven myeloid markers, is also a 
limitation. The true heterogeneity of myeloid cells is far greater than seven myeloid specific 
markers can accurately separate, especially when trying to study multiple myeloid subsets in a 
single panel. Four independent phenotypes of gut macrophages were discovered using a flow 
  72 
cytometry panel comprising seven markers (27). To conduct a large study on myeloid cells 
more definition is required. This research was only able to isolate two subsets of myeloid cells.  
 
When using a Ficoll gradient granular cells cannot be isolated (64). Granular myeloid cells 
such as neutrophils exhibit similar associations with cancer as macrophages. Due to time 
limitations and lack of parameters neutrophil were not able to be extracted from blood and 
neutrophil markers were not included in panel design. 
 
One of the main strengths of this study is the novelty. The whole workflow and development 
of analysis here is novel. Use of the high dimensional tools to analyse the myeloid cell infiltrate 
in human CRC patients is lacking.  
 
Flow cytometry is a good tool for measuring single cells in a fluid sample. The definition of 
immune cells has the potential to include up to 14 parameters with the BD LSRFortessa. This 
research also includes exciting analysis techniques. Tools that use mathematical algorithms to 
understand high dimensional relationships are important when the dataset of interest has a large 
number of features that make it difficult to manually correlate parameters. These tools will 
continue to evolve and newer platforms for analysis such as OMIQ are continuing to be 
developed. These online platforms allow researchers access to a large amount of high 
dimensional tools and may soon push these types of analysis to become more commonplace in 
areas of research where they are of most use. 
 
4.9 Summary 
Through the use of both conventional and high dimensional approaches to analysis I have 
created a novel analysis pathway specific to myeloid cells in CRC. The heterogeneity of 
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immune cells can make analysis difficult and has the potential to skew findings. These factors 
must be accounted for and considered before undertaking myeloid cell analysis. 
 
High dimensional analysis limits bias in research and can aid the discovery of novel 
populations that have not yet been defined by specific characteristics. With high dimensional 
analysis features of data can be explored in a way that conventional tools are not sufficient for. 
Myeloid cells show complexity when clustered and this is further evidence to move away from 
conventional gating analyses for complex populations.  
 
The high dimensional analysis pathway developed in this thesis (Figure 18) may in future allow 
others to study myeloid cells and quantify populations that are differentially expressed between 
the CRC tumour and NTB. These myeloid populations may then warrant further functional 
analyses and correlation to patient metadata such as disease outcomes, or stage. 
 
4.10 Future directions 
Many of the plots presented in this thesis are purely for visualisation. Quantification that has 
not been done here is the next step towards interpreting the differences seen between the plots. 
The visualisation seen in these plots are a guide for researchers. 
 
In the near future, extension of the panel to include a larger proportion of myeloid specific 
markers could be done. Mass cytometry is a variant of flow cytometry that uses antibodies 
conjugated to stable heavy metal isotopes instead of fluorophores (65). This greatly decreases 
signal overlap which allows detection of up to and above 40 parameters in one experiment 
which is useful for high parameter studies. There is also no background signal, or 
autofluorescence so does mass cytometry does not require extensive compensation. 
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Long term goals for the project are to explore myeloid cell heterogeneity to a high level. There 
is also potential for functional analyses of subsets that may be implicated in disease. Co-culture 
with tumour cells to determine how myeloid cells and tumours function and interact in an in 
vitro environment may help to understand how the TME could influence myeloid cells or vice 
versa. High resolution analysis of the myeloid cell infiltrate in CRC will provide a dataset of 
myeloid cell subpopulations that may guide further research into myeloid cell associations with 
CRC outcomes. 
 
Previous work in the lab has focused on plasticity of macrophage phenotypes in the CRC TME 
so extending that to encompass other myeloid populations may be of benefit in understanding 
the full picture of cell subsets and interactions in the TME. For this a method to isolate as many 
myeloid cells as possible would need to be designed. 
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Figure 18. Final high dimensional analysis workflow diagram. A. manual gating to remove dead cells 
and isolate CD45+ CD3- CD20- CD11b+ myeloid cells. B. dimensionality reduction on single cell data 
to visualise features and relationships in the dataset. C. FlowSOM clustering of the dataset to groups 
phenotypically similar cells into clusters and metaclusters. D. Down-sampling of data for accurate 
comparisons and colouring of single cells using flowSOM metacluster data. Manual gating in A 
undertaken using FlowJo v10. High dimensional analytic tools in B, C, and D undertaken using the 
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6 Appendices 
6.1 Introduction to mouse models 
Conventional models of cancer subcutaneously inject cancers cells into mice. The Kemp lab 
has developed a model of CRC, where tumours cells are injected into the caecum of the mouse 
during surgery (44). Animal models are not a complete representation of human disease. 
Developing an animal model that will accurately represent the immune cell infiltrate of humans 
will provide a good model for immune therapy research. Animal models with an immune 
response similar to humans will help researchers to understand what the human immune 
response to trial immunotherapies may be. 
6.2 Methods 
6.2.1 Mice 
BALB/C mice were supplied by the Hercus Taeri Research Unit, University of Otago. Mouse 
work was performed under special conditions and all mouse handing and dissections were 
performed under aseptic conditions in a class 2 biological safety cabinet. All in accordance 
with the Animal Welfare Act (1999) 
6.2.2 Mouse tissue harvest 
95% CO2 asphyxiation was used to euthanize the mice. Death was confirmed by cervical 
dislocation. Spleens, lymph nodes (inguinal, mesenteric, and brachial), and tumours were 
harvested. Immediate transfer to a 6-well plate (BD Bioscience) with RPMI and kept on ice 
until processing.  
6.2.3 Animal ethics and funding 
The University of Otago Research Grant provided funding for any mouse work undertaken. 
Ethical approval was obtained, all work was carried out under approval form the University of 
Otago Animal Ethics Committee (Protocol 19-39). 
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6.3 Titrations determine antibody concentrations for staining 
 
Figure 19. Titration data for CD14, CD33, and CD11c from top to bottom. Plots are coloured by 
density, red corresponds with high density and dark blue corresponds with low density. All antibodies 
were titrated at four concentrations (1:160, 1:80, 1:40, 1:20), however, not all concentrations are not 
shown here. Analysis was undertaken in FlowJo v10. This process was done for every antibody that 
was used for staining. 
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6.4  Manual gating removes aggregation from data 
 
Figure 20. Aggregation can be removed in initial gating steps. Here the middle box shows aggregate 
removal. Aggregates are removed by comparing makers to looking for signs of aggregation between 
two markers. Gating is used to remove aggregates of antibodies. Aggregate removal was undertaken 
in FlowJo v10. 
 
6.5 Fc receptor binding shows a large proportion of exclusive markers co-
expressed 
 
Figure 21. tSNE plots showing expression of mutually exclusive markers on single data points. From 
left to right top to bottom, tSNE plots coloured by expression of CD14, CD11b, CD3, CD20, CD11c, 
and CD33. Cells expressing high levels of the corresponding marker are red. Cells expressing low 
levels are dark blue, or light blue depending on the values on the expression axis. High expression of 
CD14, CD11b, CD3, CD33, and CD11c are seen on the same group of cells in the upper middle left of 
the tSNE plots. These markers should not be co-expressed on single groups of cells. This suggests there 
is an issue with staining. 
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6.6 Validation of limitations in cell density; frequency bias 
 
Figure 22. Validation of frequency bias in manual gating analysis. Disproportionate cell numbers can 
be misleading in conventional gating as well as high dimensional analysis. Biaxial plots showing 
expression of CD127 on the Y axis and CD206 on the X axis. Tumour, NTB, and Blood samples from a 
single CRC patient were analysed. The tumour sample showed more CD206 expression than both the 
blood and the NTB. However, the numbers of cells in the NTB samples are limited (2,268 CD14+ 
macrophages in tumour sample compared with 144CD14+  macrophages in the NTB sample). Levels 
of expression of CD206 seemed greater in the tumour sample however, the frequency of events makes 
this comparison unreliable. Analysis was undertaken in FlowJo v10. CRC, colorectal cancer. NTB non-
tumour bowel. 
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